ATIKA PHARMA SL
Company details
- Active NIF/CIF: B42991190
-
Telephone: Not available
-
Date of last BORME entry: 05/04/2024
-
Sector: Not available
-
Address: C/ VIERA Y CLAVIJO 30 -PLANTA 2 (PALMAS DE GRAN CANARIA (LAS).
-
Website: Not available
-
Featured products:
More information on ATIKA PHARMA SL
-
05/04/2024 | BORME act no.: 165346 | Register: LAS PALMASModificaciones estatutarias -
05/04/2024 | BORME act no.: 165346 | Register: LAS PALMASCambio de domicilio social
-
27/03/2023 | BORME act no.: 147919 | Register: LAS PALMASModificaciones estatutarias
-
27/01/2023 | BORME act no.: 46477 | Register: LAS PALMASAmpliación de capital
-
27/01/2023 | BORME act no.: 46477 | Register: LAS PALMASModificaciones estatutarias
-
29/03/2021 | BORME act no.: 145308 | Register: LAS PALMASConstitución
-
29/03/2021 | BORME act no.: 145308 | Register: LAS PALMASNombramientos
Other information
The CIF assigned to ATIKA PHARMA SL is B42991190, and its business status is active. The company is engaged in an economic activity classified within the CNAE -. In addition, its SIC identification - also defines it.
ATIKA PHARMA SL employs a team of Between 1 and 9 employees and generates an annual turnover of less than 2 million euros. The company is registered in the Mercantile Registry of Las palmas, and has 2 executive positions. Its most recent announcement in the Borme was published on 05/04/2024, while its last deposit of ordinary annual accounts is for the 2022 fiscal year.
To access the contact information of ATIKA PHARMA SL, such as the telephone number, postal address, or website, visit the Company Data module.
If you require more details about ATIKA PHARMA SL, we invite you to consult one of our available financial reports, the company's Annual Accounts, or to check its payment incidents in the RAI delinquency file.
The financial, business, and legal information provided about ATIKA PHARMA SL is extracted from official sources and is updated daily.
Do you want to know more about ATIKA PHARMA SL??
Find out more about this company by consulting these reports:
